deaths (OS)

metastatic/advanced RCC (mRCC) - 2nd line (L2) metastatic/advanced RCC (mRCC) - 2nd line (L2)

versus everolimus
nivolumab alone vs. everolimus 1 0.73 [0.57; 0.93], 1 RCT, I2=0% conclusive
unassessable degree of certainty